Tonix Pharmaceuticals Begins Building Lyme Disease Drug Facility in Hamilton, Montana

Tonix Pharmaceuticals broke ground on a 44-acre manufacturing facility in Hamilton on October 8, 2026.

The biotech company aims to produce TNX 4800, a Lyme disease prophylactic, while anchoring growth in the Bitterroot biotech corridor. This move signals a structural investment in local biotech infrastructure and targeted economic development.

The new facility, located on Targeted Economic Development District land, represents Tonix’s commitment to advancing treatments for complex health conditions. Seth Lederman, MD, founder of Tonix, emphasized the company’s integrated approach from discovery through FDA approval to commercialization. Local leaders, including Julie Foster of the Ravalli County Economic Development Authority, see this as a catalyst for biotech expansion. Max Baucus, former U.S. Senator and Ambassador, highlighted the company’s focus on patient-centered drug development rather than profit-driven big pharma. The building is expected to take several years to complete.

As this project unfolds, it may influence Montana’s broader economic landscape by reinforcing the state’s appeal for biotech firms. Montana’s combination of available land, a growing biotech corridor, and targeted development districts could encourage similar ventures seeking a balance of innovation and regional impact.

Tonix Pharmaceuticals breaks ground on new Hamilton manufacturing facility
By Emily Brown, KPAX News

Tonix Career Opportunities